0 63

Cited 0 times in

Efficacy and Tolerability of Telmisartan/Amlodipine and Rosuvastatin Coadministration in Hypertensive Patients with Hyperlipidemia: A Phase III, Multicenter, Randomized, Double-blind Study

Authors
 Tae-Seok Kim  ;  Seung-Woon Rha  ;  Seok-Yeon Kim  ;  Dae-Gyun Park  ;  Ki-Chul Sung  ;  Myung-Ho Yoon  ;  Kye-Hoon Kim  ;  Han-Cheol Lee  ;  Woo-Sik Kim  ;  Yong-Jin Kim  ;  Jeong-Cheon Ahn  ;  Moo-Yong Rhee  ;  Dong-Hun Cha  ;  Byung-Su Yoo  ;  Sang-Ho Park  ;  Ki-Dong Yoo  ;  Dong-Woon Jeon  ;  Young-Won Yoon  ;  Sang-Kyoon Cho  ;  Yong-Seog Oh 
Citation
 CLINICAL THERAPEUTICS, Vol.41(4) : 728-741, 2019 
Journal Title
 CLINICAL THERAPEUTICS 
ISSN
 0149-2918 
Issue Date
2019
Keywords
amlodipine ; dyslipidemia ; hypertension ; rosuvastatin ; telmisartan ; triple combination
Abstract
PURPOSE: Dyslipidemia and hypertension increase the risk for cardiovascular disease. Combination therapy improves patient compliance. This study was conducted to compare the efficacy and tolerability of the combination therapies telmisartan/amlodipine + rosuvastatin, telmisartan/amlodipine, and telmisartan + rosuvastatin in patients with hypercholesterolemia and hypertension. METHODS: In this Phase III, multicenter, 8-week randomized, double-blind study, participants with hypertension and dyslipidemia (defined as a sitting systolic blood pressure [sitSBP] of ≥140 mm Hg, a low-density lipoprotein-cholesterol [LDL-C] level of ≤250 mg/dL, and a triglyceride level of ≤400 mg/dL) were screened. After a 4-week washout/run-in period involving therapeutic lifestyle changes and telmisartan 80 mg once a day, eligible patients had a sitSBP of ≥140 mm Hg and met the LDL-C level criteria according to the National Cholesterol Education Program Adult Treatment Panel III cardiovascular disease risk category. Patients were randomly assigned to 1 of 3 groups: (1) telmisartan/amlodipine 80/10 mg + rosuvastatin 20 mg (TAR group); (2) telmisartan/amlodipine 80/10 mg (TA group); or (3) telmisartan 80 mg + rosuvastatin 20 mg (TR group). The primary efficacy end points were the percentage changes from baseline in LDL-C in the TAR and TA groups and the mean changes in sitSBP in the TAR and TR groups at week 8 compared to baseline. Continuous variables were compared using the unpaired t test or the Wilcoxon rank sum model, and categorical variables were compared using the χ2 or Fisher exact test. Tolerability was assessed based on adverse events found on physical examination including vital sign measurements, laboratory evaluations, and 12-lead ECG. FINDINGS: A total of 134 patients were enrolled. The least squares mean percentage changes in LDL-C at 8 weeks after administration of the drug compared to baseline were -51.9% (3.0%) in the TAR group and -3.2% (2.9%) in the TA group (P < 0.001). At 8 weeks after baseline, the least squares mean (SE) changes sitSBP were -28.3 (2.4) mm Hg in the TAR group and -10.7 (2.1) mm Hg in the TR group (P < 0.001). The prevalence rates of treatment-emergent adverse events were 15.0%, 25.0%, and 12.2% in the TAR, TA, and TR groups, respectively; those of adverse drug reactions were 15.0%, 22.7%, and 10.2%. None of the differences in rates were significant among 3 groups. IMPLICATIONS: Triple therapy with TAR can be an effective treatment in patients with dyslipidemia and hypertension. The TAR combination has value for hypertensive patients with hyperlipidemia in terms of convenience, tolerability, and efficacy. ClinicalTrials.gov identifier: NCT03566316.
Full Text
https://www.sciencedirect.com/science/article/pii/S0149291819300736
DOI
10.1016/j.clinthera.2019.02.013
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers
Yonsei Authors
Yoon, Young Won(윤영원) ORCID logo https://orcid.org/0000-0002-0907-0350
URI
https://ir.ymlib.yonsei.ac.kr/handle/22282913/169875
사서에게 알리기
  feedback

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse